Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Wyeth |
---|---|
Information provided by: | Wyeth |
ClinicalTrials.gov Identifier: | NCT00044772 |
The primary objective is to determine the efficacy, safety, and tolerability of venlafaxine extended release (ER) capsules in the treatment of outpatients with panic disorder (PD) in comparison to those of placebo.
Condition | Intervention | Phase |
---|---|---|
Panic Disorder |
Drug: Venlafaxine ER |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Double-Blind, Placebo-Controlled, Parallel-Group Comparison of Venlafaxine Extended-Release Capsules and Paroxetine in Outpatients With Panic Disorder |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 0600B5-399 |
Study First Received: | September 4, 2002 |
Last Updated: | May 18, 2006 |
ClinicalTrials.gov Identifier: | NCT00044772 |
Health Authority: | United States: Food and Drug Administration |
Panic Disorder |
Panic Disorder Anxiety Disorders Mental Disorders |
Venlafaxine Paroxetine Serotonin |
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Disease Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Serotonin Uptake Inhibitors |
Pharmacologic Actions Pathologic Processes Serotonin Agents Therapeutic Uses Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |